Goldman Sachs analyst Rajan Sharma introduced a Buy rating and $13.50 price target for Immatics (IMTX) after previously being Not Rated on the early-stage biotech company. The firm is positive on IMA203’s potential in melanoma given the drug’s optically higher response rates as well as greater progression free survival, or PFS, and overall survival, or OS, benefits demonstrated in a Phase 1 trial relative to competitor drugs, notes the analyst, who cites the progression of lead asset IMA203 to Phase 3 by year-end 2024 for the firm’s new rating and target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue